Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial남아프리카의 Sisonke 연구에서 의료 종사자를 대상으로 한 단회 용량 Ad26.COV2.S 백신의 안전성 평가: 3b상 시행 시험Clinical Trial Published on 2022-06-212022-09-12 Journal: PLoS Medicine [Category] MERS, 임상, 진단, [키워드] 48 hour Ad26.COV2.S vaccine adverse event AEs African age body ache breakthrough infections categories clinical clinical trials collected COVID-19 COVID-19 infection death demonstrated Effectiveness eligible evaluated expected Fever Final first vaccination Frequency HCW HCWs headache healthcare healthcare worker hospitalisations Immune system disorder implementation Implementation study IMPROVE incidence rate increasing age Infection injection site pain janssen men morbidity MOST National nervous system disorder occurred Open-label Pan participant Participants Phase 3 trials reactogenicity reactogenicity event Registered registry reported SAE SAEs safety evaluation safety profile serious AE single-arm design South South Africa Support Symptoms syndrome System thrombosis Trial triggered vaccination Vaccine [DOI] 10.1371/journal.pmed.1004024 PMC 바로가기 [Article Type] Clinical Trial
An mRNA vaccine to prevent genital herpes생식기 포진을 예방하는 mRNA 백신Review Published on 2022-04-012022-09-12 Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), SARS, 진단, [키워드] accelerated approach booster doses CD4 Cell coronavirus disease develop Developing dorsal root ganglia effective effort follicular genital HSV-1 immune responses Immunity induce Infection latency lesion memory B mRNA mRNA vaccine neutralizing antibody nucleoside-modified mRNA Phase 3 trials Prevent Prophylactic public health response robust Safe the vaccine trials trivalent Vaccine Vaccine development Vaccines while [DOI] 10.1016/j.trsl.2021.12.006 PMC 바로가기 [Article Type] Review
JAK inhibitors and COVID-19JAK 억제제 및 COVID-19Review Published on 2022-04-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] activated added Antiviral antiviral molecules Autoimmunity Baricitinib benefit clinical experience clinical trials coded concerning contributing to COVID-19 COVID-19 treatment cut-off cytokine Cytokine storm Cytokines differentiation Effect Effects Evolution family Graft hematologic hematologic neoplasms Human genome immune regulation immune response Immunosuppression immunosuppressive effect immunosuppressive effects indicated induce inhibited innate immune response interferons involved issue Jak JAK inhibitor jak inhibitors JAK1 JAK2 JAK3 JAKi janus Janus kinase kinases Meta-analysis moment Neoplasms nezulcitinib outcome pathogenic pathway Pathways patients treated patients with COVID-19 Phase 3 trials proliferation randomized clinical trial RCT reaction receptor reduce mortality rheumatic disease Rheumatic diseases risk reduction ruxolitinib SARS-COV-2 infection severe COVID-19 Side effect Signaling Significant Standard of care subsequent suggested survival the SARS-CoV-2 the WHO Therapies therapies, investigational. Tofacitinib transmembrane Treatment trials TYK2 Type I IFN type I interferons Viral viral replication virus clearance [DOI] 10.1136/jitc-2021-002838 PMC 바로가기 [Article Type] Review
Acute Calcium Pyrophosphate Crystal Arthritis of the Wrist Elicited by Anti-COVID-19 Vaccination After Carpal Tunnel Release손목 터널 방출 후 Anti-COVID-19 예방 접종으로 유발된 급성 피로인산칼슘 결정 관절염 손목염Case Reports Published on 2022-03-122022-09-11 Journal: The American journal of case reports [Category] SARS, 유전자 메커니즘, [키워드] administration anatomical Arthritis association calcium Calcium pyrophosphate carpal carpal canal Carpal Tunnel carpal tunnel syndrome Case report ChAdOx1 ChAdOx1 nCoV-19 China coding COVID-19 infection CPP crystal develop disease Efficacy effort Exacerbation expression Factor followed by illness immune response include mechanism Most patient Most patients Oxford-AstraZeneca Pain pandemic Patient phase 3 trial Phase 3 trials presenting Pyrophosphate Release required resolution of symptoms second dose severe pain shown Spike protein stiffness stimulate surgical swelling Symptom syndrome the SARS-CoV-2 the vaccine Treatment triggered Tunnel vaccination Vaccine variety wrist [DOI] 10.12659/AJCR.934833 PMC 바로가기 [Article Type] Case Reports
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial입원한 COVID-19 환자의 표준 치료와 비교한 나밀루맙 또는 인플릭시맙(CATALYST): 무작위, 다기관, 다군, 다단계, 공개 라벨, 적응형, 2상, 개념 증명 시험Clinical Trial Published on 2022-03-012022-09-12 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단, [키워드] 95% CI adaptive adverse event analysed assigned Bayesian C-reactive protein (CRP Care colony stimulating factor Complete Concentration COVID-19 CRP Efficacy enrolled Evidence FIVE greater hospital hospitalised patient Inflammation inhibitor intensive care Interaction Intervention intravenous dose investigator ISRCTN Medical Research Council multi-arm multicentre Necrosis nine occurred Open-label outcome parallel-group participant Patient Phase 3 trials Pneumonia point estimate primary endpoint Primary outcome Probability randomised Randomly recruited reducing reduction in Registered screened Standard of care stratified treatment allocation Trial usual care usual care alone usual care group with COVID-19 [DOI] 10.1016/S2213-2600(21)00460-4 PMC 바로가기 [Article Type] Clinical Trial
24. Longitudinal Assessment of Immune Responses to COVID-19 Vaccines in Solid Organ Transplant RecipientsOral Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] 95% CI anti-N IgG anti-RBD anti-S anti-S IgG Anti-S1 antibody assessment baseline black BNT162b2 board cellular response Characteristics Clinical efficacy Cohort collected consultant controls coronavirus disease COVAX COVID COVID-19 COVID-19 vaccine Cutoff DAVID demographics detect domain dose Efficacy enrolled evaluate figure first dose greater healthy healthy control humoral IgG antibodies IgG titer longitudinal magnitude median member mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 natural infection participant Pfizer Phase 3 trials plasma positive positive response prospective cohort study Quanterix Corporation RBD receive recipient recipients reducing Research respond response Result risk SARS-CoV-2 second dose serological response significantly significantly lower Simoa Solid solid organ transplant SOT spike sub-cohort subset T-cell Response table the healthy the SARS-CoV-2 threshold time timepoint timepoints titer Transplant understanding Vaccine vaccine response were excluded were used with COVID-19 [DOI] 10.1093/ofid/ofab466.024 PMC 바로가기 [Article Type] Oral Abstracts
Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle VaccinesReview Published on 2021-10-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] addressed adverse effects antiviral medication approved claimed coated COVID-19 COVID-19 transmission Critical database Diagnosis Direct Diseases elicit equipment Google Scholar immune response imperative information lack Lipid nanoparticle Masks Moderna mRNA-based nanoparticle Nanotechnology Novavax pandemic Particle Pfizer Phase 3 trials prevention Probability Protective reported SARS-CoV-2 Science Transport Treatment Vaccine Vaccines variable Virus-like particle virus-like particle vaccine virus-like particle vaccines [DOI] 10.3390/vaccines9101129 PMC 바로가기 [Article Type] Review
COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity SocietyCOVID-19 백신은 비만인에게 효과적입니다: 비만 학회의 입장 성명Article Published on 2021-10-012022-09-11 Journal: Obesity (Silver Spring, Md.) [Category] SARS, 변종, 임상, [키워드] authorization B.1.351 cause COVID-19 COVID-19 vaccine COVID-19 vaccines death demonstrated determine doses drug effective Efficacy elapsed Emergency Emergency use evaluated Evidence food Hospitalization inquiry Johnson & Johnson Moderna not significantly different obesity outcome measure outcome measures patients peer-reviewed Pfizer-BioNTech Phase 3 trials SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants scientific evidence Society South Africa submitted subpopulation Trial undergo US Food and Drug Administration vaccination Vaccine virus [DOI] 10.1002/oby.23251 PMC 바로가기 [Article Type] Article
Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical TrialsSystematic Review Published on 2021-08-232022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI 95% confidence interval accounted Adverse adverse event adverse events analyzed calculate categorical variable Chinese CIs clinical clinical trial Cochrane Library conducted control group control groups controls coronavirus disease COVID-19 COVID-19 vaccination database Effect event event rate fixed headache incidence incidence rate independent Infrastructure life-threatening Meta-analysis muscular muscular system myalgia nervous nervous system not different occurred Odds ratio Open-label participant Pearson’s chi-square test Phase 3 trials protocol random Registered review searched selected systematic review the vaccine trials vaccination Vaccine [DOI] 10.3390/vaccines9080939 PMC 바로가기 [Article Type] Systematic Review
Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH ProjectArticle Published on 2021-07-192022-10-30 Journal: Medicina [Category] COVID-19, SARS, [키워드] adverse event age and sex BNT162b2 BNT162b2 mRNA center Chronic kidney disease Community control group COVID-19 demonstrated dialysis dose Efficacy and safety FDA group Hemodialysis individual less Local male material median age medication Mild moderate mRNA vaccine objective Pain Patient patients performed Peritoneal dialysis Pfizer-BioNTech Phase 3 trials prospective cohort study questionnaire reaction reduce reported Result Safe Safety SARS-CoV-2 second dose Seven short-lived shown systemic reactogenicity Tolerance Toxicity treated vaccination Vaccine Vaccine hesitancy were assessed women [DOI] 10.3390/medicina57070732 PMC 바로가기 [Article Type] Article